Digital decision aids enter cancer prevention research for disadvantaged women
Cancer prevention only works when people can act on information, and for many socially disadvantaged women that step is still too difficult to reach. Screening uptake remains lower in these populations, mortality is higher, and the gap is not explained by biology alone. Access, health literacy, trust in the system, time constraints, and the way preventive choices are presented all shape whether a woman can move from awareness to action.
This scoping review protocol sets out to map a rapidly expanding but still fragmented area: digital Patient Decision Aids for cancer prevention in socially disadvantaged women. The focus is not on treatment after diagnosis, but on the earlier and often more difficult terrain of prevention, where shared decision-making can determine whether women engage in screening or other preventive choices at all. Digital tools are especially relevant here because they can deliver information outside the clinic visit, be tailored to patient needs, and potentially reduce barriers tied to geography, scheduling, or one-to-one counseling that is difficult to access consistently.
A narrow evidence base with broad public health stakes
The protocol defines the target population as socially disadvantaged women aged 18 to 75 in cancer prevention contexts. The age range is broad enough to capture women at different stages of preventive care engagement, from those just entering guideline-based screening windows to older women who may still face access barriers. The intervention threshold is equally specific: only digital PtDAs that meet the minimum criteria established by the International Patient Decision Aid Standards will be included.
That requirement matters because not every digital pamphlet or educational module truly functions as a decision aid. A valid PtDA should help clarify options, present benefits and harms, and support informed value-sensitive choices rather than simply broadcasting risk information. In preventive oncology, where recommendations can vary by age, risk profile, and patient preference, poorly built digital tools can easily harden confusion instead of reducing it. A structured review of what exists, how it was built, and how it was evaluated is a necessary first step before any broader implementation claims are made.
The review is designed as a scoping study rather than a narrow effectiveness analysis. That choice fits the state of the field. The investigators are not attempting to prove superiority of one digital format over another at this stage; they are mapping characteristics, development processes, and evaluation methods across the literature to show what has actually been created for this population and where the gaps remain. In an area with sparse and heterogeneous evidence, that kind of cartography is often more useful than forcing a premature efficacy judgment.
Search strategy built for breadth rather than a single trial question
The planned search is expansive. MEDLINE, CINAHL, Embase, Web of Science, Cochrane databases, Google Scholar, and gray literature sources will all be searched through a three-step strategy. Studies and sources in any language will be considered, which broadens the chance of capturing tools developed outside English-language research pipelines and reduces the risk of overlooking community-facing interventions that never reached major journals.
Two independent reviewers will handle study selection, data extraction, and analysis. Citations will be imported into Rayyan for screening, a practical choice for managing large, multi-database yields while keeping review decisions transparent. The inclusion of quantitative research, qualitative work, and gray literature is a major strength for a topic like this, because digital PtDAs may appear in published evaluations, needs assessments, implementation studies, and nontraditional reports that would otherwise be lost if only randomized or controlled evidence were considered.
The protocol also commits to JBI methodology for scoping reviews and to PRISMA-ScR reporting standards. Those frameworks matter because they force discipline in a field where terminology often blurs together patient education, decision support, risk communication, and true decision aids. A rigorous scoping method can separate those categories and show whether the available tools are genuinely designed for shared decision-making or merely repackaged educational content.
Why social disadvantage changes the design problem
Social disadvantage does not simply reduce access to cancer prevention; it changes the design requirements for digital tools. A PtDA built for highly educated, digitally fluent users may fail the very people it is intended to help. Comprehension, device access, language, cultural trust, and the burden of competing life demands all affect whether a woman can use a digital aid to make a preventive choice. In practical terms, a decision aid that assumes stable internet access, high numeracy, or long uninterrupted viewing time may never be usable in the settings where the preventive gap is widest.
That is why the protocol’s attention to development process is clinically meaningful. A review that tracks how these tools were designed may reveal whether end users were involved, whether adaptation for disadvantaged groups was explicit, and whether evaluation went beyond usability to consider acceptability and decision quality. In cancer prevention, design defects can become access defects very quickly.
A single sentence captures the central problem: a decision aid that cannot be understood, trusted, or reached does not improve prevention.
What the review can and cannot answer
Because this is a protocol, no findings are available yet, and the review is not claiming that digital PtDAs improve screening uptake or reduce cancer mortality. Its value lies in identifying what evidence exists, what populations have been reached, which preventive decisions have been addressed, and how rigorously the tools have been tested. The planned synthesis will use tables and descriptive content analysis to organize those details, which should make patterns visible across heterogeneous sources without pretending the literature is more mature than it is.
The protocol also states that findings will be shared with healthcare professionals, public health and cancer prevention stakeholders, and socially disadvantaged communities and their networks. That dissemination plan is important. In prevention research, translation fails when evidence stays locked inside academic journals and never reaches the clinicians, advocates, and community partners who actually shape screening behavior.
The remaining gap is straightforward and operational: the field still needs to establish whether existing digital PtDAs truly match the needs of disadvantaged women, or whether they replicate the same inequities in a new format. This scoping review is set up to answer the first question with precision before anyone claims the second has been solved.